Substance / Medication

Rezafungin acetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.
Kim Hannah Yejin, Nguyen Thi Anh, Kidd Sarah et al. · Med Mycol · 2024
PMID: 38935900Meta-AnalysisFull text (PMC)
Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.
Hamburger Flávio Guinsburg, Gales Ana Cristina, Colombo Arnaldo Lopes · Mycopathologia · 2024
PMID: 38940953Meta-Analysis
Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.
Srisurapanont Karan, Lerttiendamrong Bhoowit, Meejun Tanaporn et al. · Mycoses · 2024
PMID: 39379339Meta-AnalysisFull text (PMC)
Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients With Candidemia: A Systematic Review and Meta-Analysis.
Phongkhun Kasidis, Pothikamjorn Thananop, Srisurapanont Karan et al. · Clin Infect Dis · 2023
PMID: 36750934Meta-AnalysisFull text (PMC)
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review.
Vinayagamoorthy Kalaiselvi, Pentapati Kalyana Chakravarthy, Prakash Hariprasath · Mycoses · 2022
PMID: 35441748Meta-AnalysisFull text (PMC)
Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses.
Domingos Eric L, Vilhena Raquel O, Santos Josiane M M F et al. · Int J Antimicrob Agents · 2022
PMID: 35691603Meta-Analysis
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
De Rosa Francesco Giuseppe, Busca Alessandro, Capparella Maria Rita et al. · Clin Drug Investig · 2021
PMID: 33891293Meta-AnalysisFull text (PMC)
Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis.
Kato Hideo, Hagihara Mao, Shibata Yuichi et al. · J Infect Chemother · 2021
PMID: 34217605Meta-Analysis
Rezafungin Acetate.
Am J Health Syst Pharm · 2023
PMID: 37471252Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rezafungin acetate (substance)
SNOMED CT
1363063002
UMLS CUI
C4726688

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.